Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down

US Average Aggregate Net Prices Declined 7.8%

Executive Summary

The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.

You may also be interested in...



Global COVID-19 Vaccine Spending Estimated At $157bn Through 2025 By IQVIA

Vaccine spending projections represent about 2% of total spending on medicines IQVIA said. Increased spending will be partly offset by COIVD-19 disruptions, however.

Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Stock Watch: The Complex Biologics Market Is…Complex

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel